Europe Closed System Transfer Devices Market

The Europe closed system transfer devices market is projected to reach USD 0.57 billion by 2031 from USD 0.41 billion in 2026 at a CAGR of 6.8% during the forecast period.

The Europe closed system transfer devices (CSTD) market is mainly influenced by factors such as the growing consumption of oncological and hazardous drugs, the increasing awareness of the risks of occupational exposure, and the compliance with the safety standards of the EU and its member states. On the other hand, impediments include fragmented regulatory requirements across countries, budget constraints in public healthcare systems, and the slow pace of adoption in small facilities. There are significant possibilities, for example, the extended use of CSTD beyond oncology to biologics and specialty injectables, the increased usage of hospital and ambulatory infusion services, and the safety standards' harmonization in Europe, which may facilitate the rapid spread of CSTD use.

To know about the assumptions considered for the study download the pdf brochure

This report segments the CSTD market based on closing mechanism, type, component, technology, end user, and country.

Prominent players in this market include BD (US), ICU Medical (US), B. Braun Melsungen (Germany),  Corvida Medical (US), JMS (Japan), Equashield (US), Corning Incorporated (US), Terumo Corporation (Japan), Cardinal Health (US), Baxter International (US), and West Pharmaceuticals Services (US), among others.

ICU Medical (US)

ICU Medical holds an influential position in the European CSTD market, attributed to its comprehensive range of clinically validated closed system transfer devices like ChemoClave and ChemoLock, which are specifically designed to comply with the strict European safety and occupational exposure standards. The company is widely accepted in the hospitals of Europe through its distributor partnership network already in place, and the integration with its broader infusion therapy and IV systems portfolio. Pharmacy adoption of ICU Medical products is supported by the company’s commitment to workflow efficiency, device compatibility, and user-friendly designs, which are characteristics most suitable for centralized pharmacy compounding. Moreover, the growing need for universally agreed-upon hazardous drug handling procedures in Europe is a major factor behind ICU Medical's strong competitive position and its continued presence in the market.

B. Braun (GerMany)

B Braun, along with other companies, is a major contributor to the European CSTD market. This is mostly due to its long-established European origin, large-scale production facilities, and strong ties with publicly funded healthcare systems. The company provides closed-system transfer devices that are integrated with its wider infusion therapy, IV containers, and pharmacy compounding solutions, making it easy for hospitals to adopt the new workflow. B. Braun’s devices comply with the European occupational safety directives and national regulations for the handling of hazardous drugs. The company’s leadership is further enhanced by its strong brand trust and supply capabilities, as well as the possibility of bundling CSTDs with infusion and medication management systems across European hospitals and oncology centers.

BD (US)

BD significantly influences the European CSTD market through the innovative development of closed system transfer device technology and the widespread acceptance of its PhaSeal system in hospitals throughout Europe. The firm is backed by extensive clinical evidence demonstrating its ability to minimize exposure to hazardous drugs and ensure compliance with European occupational safety guidelines. The extensive sales and distribution network of BD in Europe, its strong brand recognition, and the compatibility of CSTDs with its broader medication management and infusion portfolio are among the factors that have supported the widespread adoption of the product. Moreover, BD's continual product innovation and customer training initiatives are among the factors that contribute to the company's long-term customer loyalty across Europe.

Market Ranking

The European CSTD market is consolidated, with prominent players accounting for 50.7% of the total market share in 2025. Some of the players dominating the market include BD (US), ICU Medical (US), Cardinal Health (US), B. Braun Melsungen (Germany), Corvida Medical (US), JMS (Japan), Equashield (US), Terumo Corporation (Japan), and Baxter International (US), among others.

The European CSTD market features a combination of well-established multinational players and robust regional manufacturers with a strong presence in public hospital systems. This adoption is driven by the increasing number of oncology drug preparations, the growing awareness of the risks of occupational exposure, and compliance with EU and national safety at work directives. Major players leverage the advantages of integrated infusion and pharmacy portfolios and also benefit from their long-standing relationships with hospital procurement bodies. Nevertheless, product penetration varies from one country to another due to fragmented regulations and reimbursement policies. SMEs and global manufacturers are becoming more influential by providing cost-effective, easy-to-use CSTDs, especially in hospitals operating under tight budgets and ambulatory infusion centers, resulting in fierce price competition and widening access across Europe.

Related Reports:

Europe Closed System Transfer Devices Market by Closing Mechanism (Color-to-Color System), Type (Needleless Systems), Component (Female Components, Male Luer), Technology (Air Cleaning/Filtration Devices), End User (Hospitals, Clinics) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com